ImmunityBio (IBRX) Expected to Announce Quarterly Earnings on Monday

ImmunityBio (NASDAQ:IBRX) is projected to issue its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 2, 2026 at 4:00 PM ET.

ImmunityBio Trading Up 1.0%

NASDAQ IBRX opened at $8.70 on Monday. ImmunityBio has a 1-year low of $1.83 and a 1-year high of $9.25. The firm’s fifty day simple moving average is $4.48 and its 200-day simple moving average is $3.12. The company has a market capitalization of $8.57 billion, a PE ratio of -21.22 and a beta of 0.14.

Insider Buying and Selling

In other ImmunityBio news, Director Barry J. Simon sold 151,967 shares of ImmunityBio stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the sale, the director directly owned 3,091,604 shares of the company’s stock, valued at approximately $22,259,548.80. The trade was a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christobel Selecky sold 25,000 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $7.51, for a total value of $187,750.00. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 226,967 shares of company stock worth $1,531,912. 69.48% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ImmunityBio

Several institutional investors have recently bought and sold shares of IBRX. Diversify Advisory Services LLC acquired a new position in ImmunityBio during the 2nd quarter worth $27,000. Sei Investments Co. bought a new position in ImmunityBio in the second quarter valued at about $31,000. Engineers Gate Manager LP acquired a new stake in ImmunityBio in the second quarter worth about $35,000. Kovack Advisors Inc. bought a new stake in ImmunityBio during the 4th quarter worth about $27,000. Finally, Empowered Funds LLC acquired a new position in ImmunityBio during the 4th quarter valued at about $28,000. Institutional investors own 8.58% of the company’s stock.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: European conditional approval and EU commercialization push — the European Commission granted conditional marketing authorization for ANKTIVA® in combination with BCG for BCG‑unresponsive NMIBC CIS, and ImmunityBio is opening an Irish subsidiary and signing distribution deals (Accord) to support the EU launch, which meaningfully expands addressable market and revenue runway. ImmunityBio Expands Access to ANKTIVA® in EU (BusinessWire)
• Positive Sentiment: Regional commercial expansion — ImmunityBio struck a partnership with Biopharma and Cigalah Healthcare to launch ANKTIVA® in Saudi Arabia and the broader MENA region, giving the drug local distribution partners and accelerating market entry in a sizeable oncology market. ImmunityBio Partners to Launch ANKTIVA in Saudi Arabia (BusinessWire)
• Positive Sentiment: Technical momentum — the stock is showing strong technicals (reported “golden cross” and trading well above the 200‑day average), reinforcing momentum traders and institutional interest. ImmunityBio Holds Golden Cross (Benzinga)
• Neutral Sentiment: Chairman commentary and publicity — public comments linking diplomatic efforts to commercial success have generated headlines and may sustain retail interest, but they are narrative-driven rather than new financial data. Chairman Comments on Diplomacy (MSN)
• Neutral Sentiment: Corporate finance/clinical updates referenced in coverage — some articles note follow‑up clinical programs and past convertible‑note activity; these are worth monitoring for dilution or R&D progress but contain no immediate financial details. Clinical/Convertible Note Context (MSN)
• Negative Sentiment: Investor litigation investigation — Pomerantz LLP announced an investigation into ImmunityBio on behalf of investors, which introduces legal and reputational risk that could pressure the stock if it leads to claims or disclosures. Pomerantz Investigates (PR Newswire)

Wall Street Analysts Forecast Growth

IBRX has been the subject of a number of analyst reports. D. Boral Capital reaffirmed a “buy” rating and issued a $24.00 price target on shares of ImmunityBio in a research report on Tuesday, February 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Jefferies Financial Group upped their target price on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. BTIG Research increased their price target on ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Finally, HC Wainwright boosted their price objective on shares of ImmunityBio from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.80.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.